Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899052 | 0.90 | LARS1 (0.56) | LARS1KCNH2DRD2HRH2HRH1 | |
| SCHEMBL13899056 | 0.90 | LARS1 (0.58) | LARS1KCNH2DRD2DRD3CYP1A1 | |
| SCHEMBL13899044 | 0.87 | LARS1 (0.54) | LARS1KCNH2DRD2DRD3CYP1A1 | |
| SCHEMBL3915201 | 0.83 | LARS1 (0.72) | LARS1KCNH2DRD2HRH2HRH1 | |
| SCHEMBL13898780 | 0.83 | LARS1 (0.49) | LARS1KCNH2DRD2 | |
| SCHEMBL13898776 | 0.83 | LARS1 (0.49) | LARS1KCNH2DRD2DRD3CYP1A1 | |
| SCHEMBL13899022 | 0.83 | LARS1 (0.49) | LARS1KCNH2DRD2CYP1A1 | |
| SCHEMBL13899041 | 0.83 | LARS1 (0.49) | LARS1KCNH2DRD2DRD3CYP1A1 | |
| SCHEMBL13899037 | 0.81 | LARS1 (0.47) | LARS1KCNH2DRD2 | |
| SCHEMBL13899066 | 0.80 | LARS1 (0.70) | LARS1KCNH2DRD2HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-7501445-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-03-10 | — | — | US | disclosed |
| US-20070049623-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES, A TAIWAN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049623-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES, A TAIWAN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049623-A1 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES, A TAIWAN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-7129359-B2 | Imidazolidinone compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-10-31 | — | — | US | disclosed |
| US-20040116476-A1 | for treating infection by enterovirus of the Picornaviridae family ; exemplified by: 1-[2-(4'-Chloro-biphenyl-4-yloxymethyl)-benzyl]-3-pyridin-4-yl-imidazolidin-2-one | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049623-A1 | Imidazolidinone compounds | PKN2, PKN1, EIF2AK2 | LARS1 4511/4885KCNH2 728/4885DRD2 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.